Edition:
United States

Advanced Search

Display
per page
  Report Title Date Provider Type Pgs Price

Madrigal Pharmaceuticals Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.

This report is essential reading for any serious investor, providing comprehensive financial information on a company's perfo...

29 Oct 2016 Reuters Investment Profile 12 $20.00

Value Graph: MADRIGAL PHARMA -- MDGL

28 Oct 2016 Ford Investor Services, Inc. 1 $12.00

Madrigal Pharmaceuticals

22 Oct 2016 S&P Capital IQ Quantitative Report 11 $127.00

ValuEngine Rating and Forecast Report for MDGL

Advanced academic research that brings you superior investment strategies in an actionable format. The most comprehensive and...

07 Aug 2016 ValuEngine, Inc. 11 $25.00

Synta Pharmaceuticals

23 Jul 2016 S&P Capital IQ Quantitative Report 10 $115.00

MDGL.OQ - Event Transcript of Madrigal Pharmaceuticals Inc conference call, Jun. 10, 2016 / 2:00PM ET

Edited Event Transcript of MDGL.OQ conference call, Jun. 10, 2016 / 2:00PM ET New York, Jul 25, 2016 (Thomson StreetEve...

10 Jun 2016 Thomson Reuters StreetEvents 7 $75.00

Synta Pharmaceuticals Corp. (SNTA) - Financial and Strategic SWOT Analysis Review

Synta Pharmaceuticals Corp. (SNTA) - Financial and Strategic SWOT Analysis Review Summary Synta Pharmaceuticals Corp. (Synta)...

09 Jun 2016 GlobalData 65 $300.00

Thomson Reuters Stock Report - Synta Pharmaceuticals Corp (SNTA-O)

StockReports+ gathers Thomson Reuters independent research, ratings and market data into a single report that optimizes the i...

10 May 2016 Thomson Reuters Stock Report 12 $25.00

SNTA.OQ - Event Transcript of Synta Pharmaceuticals Corp conference call, Apr. 14, 2016 / 8:30AM ET

Edited Event Transcript of SNTA.OQ conference call, Apr. 14, 2016 / 8:30AM ET Boston, Jun 21, 2016 (Thomson StreetEvent...

14 Apr 2016 Thomson Reuters StreetEvents 8 $75.00

Synta Pharmaceuticals Corp. (SNTA) - Financial and Strategic SWOT Analysis Review

Synta Pharmaceuticals Corp. (SNTA) - Financial and Strategic SWOT Analysis Review Summary Synta Pharmaceuticals Corp. (Synta)...

09 Mar 2016 GlobalData 72 $300.00